One remedy that doesn't appear in Magee's book is the apple cider vinegar cure, which has been circulating in home- and folk-medicine circles for decades and more recently has found a presence on the Internet. My friend Elizabeth, who, like me, has GERD but who, unlike me, prefers to manage it without taking a lot of medicine, got wind of this apple cider thing via a syndicated newspaper column written by Dr. More>>
Acid reflux can certainly cause a lot of pain and discomfort. Night after night, Bob would be at the toilet, vomiting all the food he had eaten a moment ago. He could not sleep well, then, and that made him totally distracted the following day. More>>
Save a few interludes imagining George as he would love to be - a baseball star in front of a cheering crowd - Stone sticks with the facts, laying details on with a trowel. In trying to play fair, or as fair as he can, he ends up in a strange no-man's land between fact and fantasy, polemic and biopic. With afigureascontroversialasW, boldness should have been the order of the day. Just ask President-elect Obama.
. More>>Starring: Neil Campbell Chad Carter Michael Cassady Jon Daly Katie Dippold Josh Fadem Brett Gelman Brian Huskey Will McLaughlin James Pumphrey Chris Stangl Angela Trimbur Kulap Vilaysack Morgan Vukovic
Written & Directed By: Matt Walsh
At the UCB Theater: 5919 Franklin Ave Los Angeles, CA 90004 (323) 908-8702 (right across from the Scientology Celebrity Center, as if you didn't know!)
Photo by cgkinla via the LAist Featured Photos pool on Flickr
. More>>Adding to those factors is uncertainty over the impact a lengthy and deepening economic downturn might have as people lose health insurance or stop filling costly prescriptions.
"The economy is one of the more prominent wild card factors in the forecast," Diana Conmy, director of Market Insights for IMS, admitted in an interview.
The U.S. market is still expected to generate 2009 sales of $292 billion to $302 billion with the worsening economy and fewer new product launches having an impact.
New product approvals are at historically low levels, IMS said, with only 25 to 30 new chemical entities slated for launch in 2009, including potentially prominent entries in the diabetes and rheumatoid arthritis arenas. More>>